Seeking Alpha

XenoPort (XNPT) says its restless leg drug Horizant is sold out, and in this case, that's a bad...

XenoPort (XNPT) says its restless leg drug Horizant is sold out, and in this case, that's a bad thing. GlaxoSmithKline (GSK), which has commercialization rights to the treatment through the end of this month, reports manufacturing delays have led to a stockout of Horizant. XNPT says it is "evaluating the impact, if any, this will have" on financial expectations. Shares -2.48% premarket. 
From other sites
Comments (1)
  • Michael Bryant
    , contributor
    Comments (5762) | Send Message
     
    I would think this would raise prices due to a shortage and be a good thing, boosting profit. Drugs are not like tablets. (MSFT)'s tablet failed due to shortage and people thus buying a tablet from competitors like (AAPL). Can't do that well with drugs.
    12 Apr 2013, 11:19 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs